Petros Pharmaceuticals In... (PTPI)
0.11
-0.03 (-18.52%)
At close: Mar 27, 2025, 3:59 PM
0.10
-10.91%
Pre-market: Mar 28, 2025, 07:05 AM EDT
Company Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics.
The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease.
The company markets its line of ED products in the form of vacuum erection device products.
Petros Pharmaceuticals, Inc. is based in New York, New York.
Petros Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Dec 2, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Fady Boctor M.B.A. |
Contact Details
Address: 1185 Avenue of the Americas New York, New York United States | |
| Website | https://www.petrospharma.com |
Stock Details
| Ticker Symbol | PTPI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001815903 |
| CUSIP Number | 71678J100 |
| ISIN Number | US71678J2096 |
| Employer ID | 85-1410058 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fady Boctor M.B.A. | President & Chief Commercial Officer |
| Mitchell S. Arnold M.B.A. | Vice President of Finance & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | DEF 14A | Filing |
| Mar 14, 2025 | PRER14A | Filing |
| Mar 07, 2025 | PRE 14A | Filing |
| Feb 26, 2025 | SCHEDULE 13G | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 8-K | Current Report |